SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-23-014988
Filing Date
2023-05-03
Accepted
2023-05-03 06:46:22
Documents
14
Period of Report
2023-05-03
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K gthx-20230503.htm   iXBRL 8-K 37178
2 EX-99.1 pressrelease-1q23financial.htm EX-99.1 63963
6 g1_logox2022xrega.jpg GRAPHIC 307168
  Complete submission text file 0001628280-23-014988.txt   668390

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT gthx-20230503.xsd EX-101.SCH 1920
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT gthx-20230503_lab.xml EX-101.LAB 24849
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT gthx-20230503_pre.xml EX-101.PRE 13058
8 EXTRACTED XBRL INSTANCE DOCUMENT gthx-20230503_htm.xml XML 11842
Mailing Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709
Business Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709 919-213-9835
G1 Therapeutics, Inc. (Filer) CIK: 0001560241 (see all company filings)

IRS No.: 263648180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38096 | Film No.: 23881587
SIC: 2834 Pharmaceutical Preparations